CAPLIN POINT LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,290 INR | -0.12% |
|
-0.98% | -4.91% |
| May. 24 | Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution | MT |
| May. 16 | Caplin Point Laboratories to Seek Acquisitions | CI |
| Sales 2024 | 16.94B 203M | Sales 2025 * | 19.67B 236M | Capitalization | 97.94B 1.17B |
|---|---|---|---|---|---|
| Net income 2024 | 4.57B 54.8M | Net income 2025 * | 5.23B 62.65M | EV / Sales 2024 | 5.91 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.98 x |
| P/E ratio 2024 |
22
x | P/E ratio 2025 * |
18.7
x | Employees | 1,642 |
| Yield 2024 * |
0.24% | Yield 2025 * |
0.26% | Free-Float | 25.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Caplin Point Laboratories Limited
| 1 day | -0.12% | ||
| 1 week | -0.98% | ||
| 1 month | -4.90% | ||
| 3 months | -13.16% | ||
| 6 months | +2.89% | ||
| Current year | -4.91% |
1 week
1 280.75
1 327.60
1 month
1 250.051 390.15
Current year
1 240.001 617.80
1 year
756.101 617.80
3 years
575.001 617.80
5 years
180.001 617.80
10 years
32.241 617.80
| Managers | Title | Age | Since |
|---|---|---|---|
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 15-03-27 |
D. Muralidharan
DFI | Director of Finance/CFO | - | 16-02-18 |
Anto V.
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
| Chief Operating Officer | - | 10-11-30 | |
Sridhar Ganesan
CEO | Chief Executive Officer | 69 | 15-03-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,290 | -0.12% | 2,247 |
| 24-05-30 | 1,291 | -1.39% | 6,809 |
| 24-05-29 | 1,309 | +1.42% | 9,881 |
| 24-05-28 | 1,291 | -0.27% | 7,484 |
| 24-05-27 | 1,295 | -0.60% | 3,088 |
Delayed Quote Bombay S.E., May 31, 2024 at 06:00 am EDT
More quotes
Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Companyâs subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,290
INR
Average target price
1,579
INR
Spread / Average Target
+22.46%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.91% | 1.17B | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -9.58% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- CAPLIPOINT Stock
